These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

260 related items for PubMed ID: 8391674

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Intravitreal foscarnet for cytomegalovirus retinitis in a patient with acquired immunodeficiency syndrome.
    Pearson PA, Jaffe GJ, Ashton P.
    Am J Ophthalmol; 1993 May 15; 115(5):686-8. PubMed ID: 8387726
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. A randomized, controlled trial of foscarnet in the treatment of cytomegalovirus retinitis in patients with AIDS.
    Palestine AG, Polis MA, De Smet MD, Baird BF, Falloon J, Kovacs JA, Davey RT, Zurlo JJ, Zunich KM, Davis M.
    Ann Intern Med; 1991 Nov 01; 115(9):665-73. PubMed ID: 1656826
    [Abstract] [Full Text] [Related]

  • 25. Phase II dose-ranging trial of foscarnet salvage therapy for cytomegalovirus retinitis in AIDS patients intolerant of or resistant to ganciclovir (ACTG protocol 093). AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases.
    Jacobson MA, Wulfsohn M, Feinberg JE, Davis R, Power M, Owens S, Causey D, Heath-Chiozzi ME, Murphy RL, Cheung TW.
    AIDS; 1994 Apr 01; 8(4):451-9. PubMed ID: 8011248
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Cytomegalovirus disease in AIDS: the Edinburgh experience.
    Cheong I, Flegg PJ, Brettle RP, Welsby PD, Burns SM, Dhillon B, Leen CL, Gray JA.
    Int J STD AIDS; 1992 Apr 01; 3(5):324-8. PubMed ID: 1327173
    [Abstract] [Full Text] [Related]

  • 30. Clinically resistant cytomegalovirus retinitis.
    Flores-Aguilar M.
    Semin Ophthalmol; 1995 Jun 01; 10(2):142-9. PubMed ID: 10155627
    [No Abstract] [Full Text] [Related]

  • 31. Diagnosis and treatment of cytomegalovirus retinitis.
    Henderly DE, Jampol LM.
    J Acquir Immune Defic Syndr (1988); 1991 Jun 01; 4 Suppl 1():S6-10. PubMed ID: 1848624
    [Abstract] [Full Text] [Related]

  • 32. Studies of ocular complications of AIDS Foscarnet-Ganciclovir Cytomegalovirus Retinitis Trial: 1. Rationale, design, and methods. AIDS Clinical Trials Group (ACTG).
    Control Clin Trials; 1992 Feb 01; 13(1):22-39. PubMed ID: 1315661
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Evaluation of cytomegalovirus retinitis management. Outcome of four years of cytomegalovirus therapy.
    Ries E, Mühlbauer B, Ruhswurm I, Krepler K, Derbolav A, Svolba G, Rieger A, Wedrich A.
    Ophthalmologica; 1998 Feb 01; 212(4):239-43. PubMed ID: 9672212
    [Abstract] [Full Text] [Related]

  • 35. Ocular complications of the acquired immunodeficiency syndrome. Focus on the treatment of cytomegalovirus retinitis with ganciclovir and foscarnet.
    Keijer WJ, Burger DM, Neuteboom GH, Vrooland JL, Meenhorst PL, Koks CH, Beijnen JH.
    Pharm World Sci; 1993 Apr 23; 15(2):56-67. PubMed ID: 8387852
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Increased survival of a cohort of patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis who received sodium phosphonoformate (foscarnet).
    Polis MA, deSmet MD, Baird BF, Mellow S, Falloon J, Davey RT, Kovacs JA, Palestine AG, Nussenblatt RB, Masur H.
    Am J Med; 1993 Feb 23; 94(2):175-80. PubMed ID: 8381583
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.